IDEAYA Biosciences Inc. (IDYA)
NASDAQ: IDYA
· Real-Time Price · USD
25.84
0.15 (0.58%)
At close: Sep 26, 2025, 11:05 AM
0.58% (1D)
Bid | 25.81 |
Market Cap | 2.27B |
Revenue (ttm) | 7M |
Net Income (ttm) | -331.03M |
EPS (ttm) | -3.84 |
PE Ratio (ttm) | -6.73 |
Forward PE | -7.73 |
Analyst | Buy |
Dividends | n/a |
Ask | 25.93 |
Volume | 312,790 |
Avg. Volume (20D) | 1,126,882 |
Open | 26.00 |
Previous Close | 25.69 |
Day's Range | 25.54 - 26.05 |
52-Week Range | 13.45 - 32.67 |
Beta | 0.12 |
Ex-Dividend Date | n/a |
About IDYA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IDYA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IDYA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsIDEAYA Biosciences Inc. is scheduled to release its earnings on
Nov 3, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+5.77%
IDEAYA Biosciences shares are trading higher. Cant...
Unlock content with
Pro Subscription
3 weeks ago
+3.79%
IDYA stock has given up its prior gain. Ideaya Biosciences shares were trading higher after the company announced an exclusive license agreement with Servier for Darovasertib for rare eye cancer.